R
Ronald F van Vollenhoven
Researcher at University of Amsterdam
Publications - 354
Citations - 32567
Ronald F van Vollenhoven is an academic researcher from University of Amsterdam. The author has contributed to research in topics: Rheumatoid arthritis & Medicine. The author has an hindex of 72, co-authored 309 publications receiving 26884 citations. Previous affiliations of Ronald F van Vollenhoven include Karolinska Institutet & Karolinska University Hospital.
Papers
More filters
Journal ArticleDOI
Belimumab in the treatment of systemic lupus erythematosus: high disease activity predictors of response
Ronald F van Vollenhoven,Michelle A. Petri,Ricard Cervera,David M. Roth,Beulah Ji,Christi Kleoudis,Z. John Zhong,William W. Freimuth +7 more
TL;DR: It is suggested that belimumab has greater therapeutic benefit than standard therapy alone in patients with higher disease activity, anti-dsDNA positivity, low complement or corticosteroid treatment at baseline.
Journal ArticleDOI
The frequency and outcome of lupus nephritis: results from an international inception cohort study
John G. Hanly,Aidan G. O'Keeffe,Li Su,Murray B. Urowitz,Juanita Romero-Diaz,Caroline Gordon,Sang Cheol Bae,Sasha Bernatsky,Ann E. Clarke,Daniel J. Wallace,Joan T. Merrill,David A. Isenberg,Anisur Rahman,Ellen M. Ginzler,Paul R. Fortin,Dafna D. Gladman,Jorge Sanchez-Guerrero,Michelle Petri,Ian N. Bruce,Mary Anne Dooley,Rosalind Ramsey-Goldman,Cynthia Aranow,Graciela S. Alarcón,Barri J. Fessler,Kristjan Steinsson,Ola Nived,Gunnar Sturfelt,Susan Manzi,Munther A. Khamashta,Ronald F van Vollenhoven,Asad Zoma,Manuel Ramos-Casals,Guillermo Ruiz-Irastorza,S. Sam Lim,Thomas Stoll,Murat Inanc,Kenneth C. Kalunian,Diane L. Kamen,Peter J. Maddison,Christine A. Peschken,Søren Jacobsen,Anca Askanase,Chris Theriault,Kara Thompson,Vernon T. Farewell +44 more
TL;DR: Despite current standard of care, nephritis was associated with ESRD and death, and renal insufficiency was linked to lower health-related quality of life.
Journal ArticleDOI
Safety and Efficacy of Additional Courses of Rituximab in Patients With Active Rheumatoid Arthritis An Open-Label Extension Analysis
Edward C. Keystone,Roy Fleischmann,Paul Emery,Daniel E. Furst,Ronald F van Vollenhoven,Joan M. Bathon,Maxime Dougados,Andrew R. Baldassare,Gianfranco Ferraccioli,Andrew Chubick,James Udell,M. Cravets,Sunil Agarwal,Simon Cooper,Fabio Magrini +14 more
TL;DR: Findings indicate that patients treated with repeated courses of rituximab have sustained clinical responses with no new adverse events.
Journal ArticleDOI
Integrated safety in tocilizumab clinical trials.
Michael Schiff,Joel M. Kremer,Angelika Jahreis,E. Vernon,John D. Isaacs,Ronald F van Vollenhoven +5 more
TL;DR: The longer-term safety profile of tocilizumab (mean treatment duration, 2.4 years) is consistent with that observed in the phase 3 studies (duration up to 1 year); no increase with prolonged exposure was noted.
Journal ArticleDOI
Longterm safety of patients receiving rituximab in rheumatoid arthritis clinical trials
Ronald F van Vollenhoven,Paul Emery,Clifton O. Bingham,Edward C. Keystone,Roy Fleischmann,Daniel E. Furst,Katherine Macey,Marianne T. Sweetser,Ariella Kelman,Ravi Rao +9 more
TL;DR: In this longterm safety update in RA clinical trial patients, rituximab remained well tolerated over multiple courses, and infections and infections remained stable over time and by treatment course.